187 related articles for article (PubMed ID: 21298859)
1. [The JUPITER study: critical review of final results].
Urbinati S; Romanazzi S; Gambetti S
G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):28S-32S. PubMed ID: 21298859
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
3. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
4. [The JUPITER study: background and research hypotheses].
Rapezzi C; Gallo P
G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):25S-27S. PubMed ID: 21298858
[TBL] [Abstract][Full Text] [Related]
5. [JUPITER, what now?].
Perna GP
G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):33S-38S. PubMed ID: 21298860
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Fonseca FA; Izar MC
Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
Michos ED; Blumenthal RS
J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
[TBL] [Abstract][Full Text] [Related]
8. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
9. A tale of three labels: translating the JUPITER trial data into regulatory claims.
Ridker PM
Clin Trials; 2011 Aug; 8(4):417-22. PubMed ID: 21835857
[TBL] [Abstract][Full Text] [Related]
10. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
[TBL] [Abstract][Full Text] [Related]
11. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
Ridker PM;
Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
[No Abstract] [Full Text] [Related]
13. The JUPITER trial: How will it change clinical practice?
Watson KE
Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
[TBL] [Abstract][Full Text] [Related]
14. The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?
Sgueglia GA; Crea F
J Cardiovasc Med (Hagerstown); 2011 Jan; 12(1):66-70. PubMed ID: 21139510
[TBL] [Abstract][Full Text] [Related]
15. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
16. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
O'Keefe JH; Carter MD; Lavie CJ; Bell DS
Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
[TBL] [Abstract][Full Text] [Related]
17. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Ridker PM; Danielson E; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Macfadyen JG; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Lancet; 2009 Apr; 373(9670):1175-82. PubMed ID: 19329177
[TBL] [Abstract][Full Text] [Related]
18. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
19. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
Scheen AJ
Rev Med Liege; 2008 Dec; 63(12):749-53. PubMed ID: 19180837
[TBL] [Abstract][Full Text] [Related]
20. Another look at the results of the JUPITER trial.
Kappagoda CT; Amsterdam EA
Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]